SV2005001840A - Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - docket 17005 - Google Patents

Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - docket 17005

Info

Publication number
SV2005001840A
SV2005001840A SV2004001840A SV2004001840A SV2005001840A SV 2005001840 A SV2005001840 A SV 2005001840A SV 2004001840 A SV2004001840 A SV 2004001840A SV 2004001840 A SV2004001840 A SV 2004001840A SV 2005001840 A SV2005001840 A SV 2005001840A
Authority
SV
El Salvador
Prior art keywords
compounds
formula
docket
treatment
neurodegenerative disorders
Prior art date
Application number
SV2004001840A
Other languages
English (en)
Inventor
Yuhpyng L Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2005001840A publication Critical patent/SV2005001840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPUESTOS DE FORMULA (VER FORMULA) EN DONDE R3, R5, R6, R7 Y Z, ASI COMO OTROS VALORES ENUMERADOS CON RELACION A R3, R5, R6, R7 Y Z SON COMO SE LOS DEFINE. LOS COMPUESTOS DE FORMULA I PRESENTAN ACTIVIDAD INHIBIDORA DE LA PRODUCCION DE PEPTIDO ABETA. ESTA INVENCION SE REFIERE ADEMAS A COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR ENFERMEDADES, POR EJEMPLO, ENFERMEDADES NEURODEGENERATIVAS, I.E. ENFERMEDAD DE ALZHEIMER, EN UN MAMIFERO, QUE COMPRENDEN COMPUESTOS DE FORMULA I.
SV2004001840A 2003-08-06 2004-08-09 Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - docket 17005 SV2005001840A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49288403P 2003-08-06 2003-08-06
US49802803P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
SV2005001840A true SV2005001840A (es) 2005-11-04

Family

ID=34197958

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2004001840A SV2005001840A (es) 2003-08-06 2004-08-09 Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - docket 17005

Country Status (13)

Country Link
US (1) US7112599B2 (es)
EP (1) EP1653952A4 (es)
JP (1) JP2007501244A (es)
AR (1) AR046327A1 (es)
BR (1) BRPI0413349A (es)
CA (1) CA2534529A1 (es)
MX (1) MXPA06001480A (es)
PA (1) PA8608601A1 (es)
PE (1) PE20050337A1 (es)
SV (1) SV2005001840A (es)
TW (1) TW200510351A (es)
UY (1) UY28458A1 (es)
WO (1) WO2005016267A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50595B (sr) * 2004-03-23 2010-05-07 Pfizer Products Incorporated Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja
US20050222227A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
EP1940802A2 (en) * 2005-09-22 2008-07-09 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
EA201791271A1 (ru) * 2012-05-31 2018-01-31 Фенекс Фармасьютикалз Аг ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
EP3768269A4 (en) * 2018-03-23 2022-03-23 Yumanity Therapeutics, Inc. COMPOUNDS AND THEIR USES
CN113651805B (zh) * 2021-07-19 2023-07-25 安徽医科大学 一种1,2,4-噁二唑-吡啶类化合物及其在治疗阿尔茨海默症中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3094462A (en) * 1961-09-18 1963-06-18 Mcneilab Inc Therapeutic reaction complex for muscle relaxation
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
GB1264258A (es) * 1970-10-10 1972-02-16
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
KR20000005291A (ko) * 1996-06-25 2000-01-25 다케다 야쿠힌 고교 가부시키가이샤 옥사졸론 유도체 및 항-헬리코박터 파일로리 제제로서의 이의용도
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
WO2000059285A2 (en) * 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
CN1688557A (zh) * 2002-10-09 2005-10-26 辉瑞产品公司 用于治疗神经变性疾病的噻唑化合物
CA2501799C (en) * 2002-10-09 2008-06-17 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
AU2003298195B8 (en) * 2002-12-23 2009-04-23 F. Hoffmann-La Roche Ag Oxazoles as mGluR1 enhancer
PL378343A1 (pl) * 2003-01-13 2006-03-20 F. Hoffmann-La Roche Ag Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny

Also Published As

Publication number Publication date
WO2005016267A2 (en) 2005-02-24
AR046327A1 (es) 2005-12-07
PA8608601A1 (es) 2005-03-03
PE20050337A1 (es) 2005-06-06
JP2007501244A (ja) 2007-01-25
CA2534529A1 (en) 2005-02-24
MXPA06001480A (es) 2006-05-15
EP1653952A4 (en) 2007-04-04
BRPI0413349A (pt) 2006-10-10
US20050032859A1 (en) 2005-02-10
EP1653952A2 (en) 2006-05-10
WO2005016267A3 (en) 2005-04-21
UY28458A1 (es) 2005-03-31
US7112599B2 (en) 2006-09-26
TW200510351A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
CR7785A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
PA8608301A1 (es) Compuestos heteroarilo de 6 miembros de heteroarilo para el tratamiento de enfermedades neurogenerativas
SV2006002055A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
UY28144A1 (es) Agentes terapéuticos
GT200400076A (es) Ligandos de receptores de cannabinoides y sus usos
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
DOP2005000049A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegererativos
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
DOP2003000765A (es) Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease
SV2005001840A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - docket 17005
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2004000966A (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos
PA8601101A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
EA200500382A1 (ru) Соединения тиазола для лечения нейродегенеративных расстройств
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos

Legal Events

Date Code Title Description
FD Lapse